CSI Market
Sign In | Register

Cellular Biomedicine Group Inc (CBMG) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CBMG Annual Cash Flow →
Tracking cash flow results across Cellular Biomedicine Group Inc to Sep 30 2019 helps illustrate how Sep 30 2020's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2020)
9 Months 		(Jun 30 2020) (Mar 31 2020) (Dec 31 2019) (Sep 30 2019)
Operating Activities
Income-42.12
Depreciation & amortization4.85
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.24
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation2.70
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Value Of Stock Received For Services-
Loss On Extinguishment Of Debt-
Deferred Compensation Arrangement With Individual Compensation Expense-
Amortization Of Deferred Charges-
Loss On Disposal Of Investments-
Equity Method Investment Other Than Temporary Impairment-
Impairment Of Investments-
Interest Expense-
Interest Expense Deposits From Other Federal Home Loan Banks-
Income taxes0.00
Realized Investment Gains (Losses), Total0.00
Accounts Receivable0.43
Increase (Decrease) in Accounts Payable1.02
Increase (Decrease) in Accrued Liabilities-0.21
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.66
Other Working Capital0.58
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-33.17
Investing Activities
Capital Expenditures-0.18
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Assets-
Payments For Purchase Of Other Assets-
Increase (Decrease) in Restricted Cash-6.41
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Assets, Investing Activities-7.06
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net6.41
Discontinued operations0.00
Net Cash Flow from Investing Activities-7.23
Financing Activities
Short-term debt Net33.54
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.53
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net-32.44
Advances From Affiliate-
Repayment Of Advances From Affiliate-
Stock Repurchased During Period Value-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents32.44
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities34.06
Effect of exchange rate on cash flow-0.07
Discontinued operations0.00
Free Cash Flow-33.35
Total Cash Flow26.03
4 historic quarters locked

Sign in to unlock the full Cellular Biomedicine Group Inc cash flow history.

Sign In Create Free Account

About CBMG Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.